CEVEC aims to become the leading independent player for human cell line based clinical materials. CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of biopharmaceuticals.

CEVEC – human cells for human pharmaceuticals

Human cell-based expression systems have a huge potential for the expression and production of complex human therapeutic proteins. However, the number of human non-tumor derived cell types, which can be immortalized to stable high producer cells is very limited. CEVEC developed CAP Cells, based on normal human amniocytes and known to be highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. Primary human amniocytes have been immortalized by adenoviral genetic E1/pIX functions and selected for highly efficient CAP (CEVEC’s Amniocyte Production) cell lines. Using CEVEC’s CAP Cells, proteins are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Glycosylation is one of the most important post-translational modifications (PTM) of biopharmaceutical proteins. Indeed, more than half of all human proteins are glycosylated, and the glycan structures often play important roles in glycoprotein structure, function and half-life. CAP Technology based on human amniocytes offers major advantages, including original human glycosylation for complex proteins, authentic sialylation for sustained half-live, no immunogenic non-human carbohydrate residues, etc… This patented technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines. A master cell bank (MCB) of CAP Cells growing in suspension has been established, tested and certified according to ICH guidelines and European Pharmacopeia.

CEVEC is based in Köln (Germany). Management Team is composed by Wolfgang Kintzel (CEO), Frank Ubags (COO), Nicole Faust (CSO) and Hartmut Tintrup. Board is composed by Joachim Rautter, Aristotelis Nastos, Rainer Christine, Christian Leikert, Stefan Kochanek and Klaus Zimmermann. CEVEC´s intellectual property on amniocyte technology is protected worldwide within three patent families. CEVEC Pharmaceuticals recently offered its new cGMP compliant Contract Manufacturing Services. CAP-derived clinical material can be provided for phase I-II studies, including protein, vaccine, virus or gene therapy vector.

More about CEVEC : http://cevec.com/

CEVEC – human cell line based clinical materials – human amniocyte based protein expression platform CAP – human cells for human pharmaceuticals – human cell-based expression systems – production complex human therapeutic protein – human amniocytes – CAP

CEVEC – human cell line based clinical material – human amniocyte based protein expression platform – CAP – human amniocyte based protein expression – amniocyte based protein expression – amniocyte protein expression – protein expression – human cells human pharmaceuticals – human cells – human pharmaceuticals – human cell-based expression system – production complex human therapeutic proteins – human amniocyte – amniocyte – glycoproteins – glycoprotein – primary human amniocytes – primary human amniocyte – CEVEC’s Amniocyte Production – CEVEC Amniocyte Production – authentic post-translational modifications – serum-free suspension culture – glycosylation – PTM – original human glycosylation – authentic sialylation – sialylation – master cell bank – MCB – Wolfgang Kintzel – Frank Ubags – Nicole Faust – Hartmut Tintrup – Joachim Rautter – Aristotelis Nastos – Rainer Christine – Christian Leikert – Stefan Kochanek – Klaus Zimmermann – cGMP compliant Contract Manufacturing Services